Clinical trials: Thyroid Neoplasm
Thyroid Cancer
This Study is Mainly About Finding Incidence Among Other Factors of Thyroid Cancer in Patient with Benign Disease As MNG to Early Discover of the Malignancy to Save the Patient from Aggressive Procedure
The purpose of the present study was to evaluate the prevalence of thyroid cancer in patients who had thyroidectomy for MNG, and analyze patient-related parameters to identify type and risk factors associated with incidental…
- Trial name
- NCT06730971
- Testing
- Total thyroidectomy
- Volunteers
- 300 people
- Sponsor
- Asmaa Mohamed Emam
Recurrent Malignant Solid Neoplasm, Recurrent Melanoma
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment.
- Conditions
- Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma
- Trial name
- NCT01709435
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 23 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Brain Neoplasms, Lung Neoplasms
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Brain Neoplasms, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00123760
- Testing
- Positron Emission Tomography (PET) scan
- Where
- Canada
- Volunteers
- 10,838 people
- Sponsor
- AHS Cancer Control Alberta
Thyroid Cancer
Dental Safety Profile of High-Dose Radioiodine Therapy
We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.
- Trial name
- NCT00439478
- Testing
- Radioiodine
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- University Hospital, Basel, Switzerland
Differentiated Thyroid Cancer
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Background: BRAFV600E is the most frequent oncogene in differentiated thyroid cancer (DTC) occurring in about 50% of cases. Clinical trials with tyrosine kinase inhibitors (TKI) with specific activity against BRAF in metastatic…
- Trial name
- NCT01700699
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Salerno
Head and Neck Cancer
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004048
- Testing
- filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Differentiated Thyroid Cancer
Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer. Patients will be identified via oncology multidisciplinary team meetings.
- Trial name
- HoT (NCT05604963)
- Testing
- Total Thyroidectomy, Hemithyroidectomy
- Where
- 33 sites in United Kingdom
- Volunteers
- 456 people
- Sponsor
- University College, London
Thyroid Cancer
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
- Trial name
- NCT04309136
- Testing
- Anlotinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Fudan University
Melanoma, Non-Small-Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
- Trial name
- NCT05355701
- Testing
- PF-07799933, binimetinib, cetuximab
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Thyroid Abnormalities, Thyroid
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration
The goal of this observational study is to evaluate the diagnostic accuracy and clinical workflow integration of an ultrasound intelligent agent (UIA) for thyroid disease management in a real-world multicenter setting.
- Conditions
- Thyroid Abnormalities, Thyroid, Thyroid Cancer
- Trial name
- NCT07296575
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Nanchang University
Thyroid Cancer
New Thyroid Fine Needle Aspiration Biopsy Apparatus
Evaluation of the effectivity of the new thyroid fine needle aspiration biopsy (FNAB) apparatus of which patented from Turkish Patent Institute.
- Trial name
- fnab (NCT01512212)
- Testing
- biopsy
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- SB Istanbul Education and Research Hospital
Thyroid Cancer
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.
- Trial name
- NCT06730529
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Thyroid Papillary Carcinoma
A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma
To establish and validate a suitable and practical nomogram for primary hospitals to predict the risk of central lymph node metastasis (CLNM) among thyroid papillary carcinoma (PTC) patients based on clinical and ultrasound…
- Trial name
- NCT05191927
- Testing
- male
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Neoplasm of Thyroid Gland
Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.
Scientific objectives: Primary objective: To assess if the use of IONM can decrease the rates of temporary RLN palsy after thyroid cancer surgery Secondary objectives: To assess if the use of IONM can decrease permanent RLN palsy…
- Trial name
- ACTION (NCT04842994)
- Testing
- IONM tube
- Where
- India
- Volunteers
- 448 people
- Sponsor
- Tata Memorial Hospital
Thyroid Neoplasms
Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer
A retrospective analysis was conducted on RAIR-DTC patients who underwent radioactive 125I seed implantation from January 2015 to February 2022 at Jiangxi Cancer Hospital. Prescription dose: 80~120 Gy.
- Trial name
- NCT06362772
- Testing
- Iodine-125 brachytherapy
- Volunteers
- 36 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Suspicious for Papillary Thyroid Carcinoma
Role of Cytomorphometry and BRAFV600E Immunocytochemistry With a Cytologic Diagnosis "Suspicious for Papillary Thyroid Carcinoma"
Thyroid nodules (TNs) are a common finding, detected by ultrasound in about 70% of healthy individuals, with women being four times more affected.
- Trial name
- NCT06901908
- Volunteers
- 45 people
- Sponsor
- Assiut University
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.